Biomedical International R D

Biomedical International R D is a biotechnology research company based in Slovakia that focuses on the development of novel diagnostic and therapeutic agents for oncology. The company specializes in targeting carbonic anhydrase IX (CA IX), a protein highly expressed in hypoxic solid tumors and associated with poor prognosis and metastasis. Their research efforts are directed toward creating high-affinity inhibitors and antibodies that can be used for both the imaging and treatment of aggressive cancers. By leveraging expertise in tumor hypoxia and enzyme inhibition, the company aims to provide precision medicine solutions for difficult-to-treat malignancies.